Celera Diagnostics’ head of discovery research talks about FDA leading the charge, the need for biomarker validation, and why the conversation should be about targeted — but not personalized — medicine.

As vice president of discovery research at Celera Diagnostics, John Sninsky has a bird’s eye view of how biomarker-based molecular diagnostics are faring in these early days. GT’s Jeanene Swanson caught up with Sninsky for a chat about biomarker validation, getting diagnostics through FDA and to physicians, and more.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.